|
1.
|
McDonagh EM, Whirl-Carrillo M, Garten Y,
Altman RB and Klein TE: From pharmacogenomic knowledge acquisition
to clinical applications: the PharmGKB as a clinical
pharmacogenomic biomarker resource. Biomark Med. 5:795–806.
2011.PubMed/NCBI
|
|
2.
|
Fujita H, Ohuchida K, Mizumoto K, et al:
Gene expression levels as predictive markers of outcome in
pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
Neoplasia. 12:807–817. 2010.PubMed/NCBI
|
|
3.
|
Maréchal R, Mackey JR, Lai R, et al:
Deoxycitidine kinase is associated with prolonged survival after
adjuvant gemcitabine for resected pancreatic adenocarcinoma.
Cancer. 116:5200–5206. 2010.PubMed/NCBI
|
|
4.
|
Sekine S, Shimada Y, Nagata T, et al:
Establishment and characterization of a new human gallbladder
carcinoma cell line. Anticancer Res. 32:3211–3218. 2012.PubMed/NCBI
|
|
5.
|
Sandler AB, Kindler HL, Einhorn LH, et al:
Phase II trial of gemcitabine in patients with previously untreated
metastatic cancer of the esophagus or gastroesophageal junction.
Ann Oncol. 11:1161–1164. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Urba SG, Chansky K, van Veldhuizen PJ, et
al: Gemcitabine and cisplatin for patients with metastatic or
recurrent esophageal carcinoma: a southwest oncology group study.
Invest New Drugs. 22:91–97. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Kroep JR, Pinedo HM, Giaccone G, Van
Bochove A, Peters GJ and Van Groeningen CJ: Phase II study of
cisplatin preceding gemcitabine in patients with advanced
oesophageal cancer. Ann Oncol. 15:230–235. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Morgan-Meadows S, Mulkerin D, Berlin JD,
et al: A phase II trial of gemcitabine 5-fluorouracil and
leucovorin in advanced esophageal carcinoma. Oncology. 69:130–134.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Fukuoka J, Fujii T, Shih JH, et al:
Chromatin remodeling factors and BRM/BRG1 expression as prognostic
indicators in non-small cell lung cancer. Clin Cancer Res.
10:4314–4324. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Nagata T, Shimada Y, Sekine S, et al:
Prognostic significance of NANOG and KLF4 for breast cancer. Breast
Cancer. Apr. 17–2012.(E-pub ahead of print).
|
|
11.
|
Sebastiani V, Ricci F, Rubio-Viqueira B,
et al: Immunohistochemical and genetic evaluation of deoxycytidine
kinase in pancreatic cancer: relationship to molecular mechanisms
of gemcitabine resistance and survival. Clin Cancer Res.
12:2492–2497. 2006. View Article : Google Scholar
|
|
12.
|
Williamson SK, McCoy SA, Gandara DR, et
al: Phase II trial of gemcitabine plus irinotecan in patients with
esophageal cancer: a Southwest Oncology Group (SWOG) Trial. Am J
Clin Oncol. 29:116–122. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Lowy AM, Firdaus I, Roychowdhury D, et al:
A phase II study of sequential neoadjuvant gemcitabine and
paclitaxel, radiation therapy with cisplatin and 5-fluorouracil and
surgery in locally advanced esophageal carcinoma. Am J Clin Oncol.
29:555–561. 2006. View Article : Google Scholar
|
|
14.
|
Fleming DR, Glisson SD, Bhupalam L,
Michelson GD, Goldsmith GH and LaRocca RV: Phase I study of
paclitaxel and day 1/day8 gemicitabine in patients with solid
malignancies. Am J Clin Oncol. 23:349–352. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Millar J, Scullin P, Morrison A, et al:
Phase II study of gemcitabine and cisplatin in locally
advanced/metastatic oesophageal cancer. Br J Cancer. 93:1112–1116.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Huang J, Fan QX, Chen L, et al: Long-term
outcomes of gemcitabine and cisplatin in patients with recurrent or
metastatic esophageal squamous cell carcinoma: a phase II trial.
Chin Med J (Engl). 124:4012–4017. 2011.PubMed/NCBI
|
